White Paper

Strengthening The Drug Manufacturing Supply Chain During Extraordinary Times

Map global Logistics GettyImages-1202209630

The Covid-19 pandemic placed unprecedented strain on the biopharmaceutical supply chain as the accelerated development of drugs and vaccines drove a surge in demand for raw materials. This demand outstripped the global manufacturing capacity of the entire supply chain resulting in shortages that were compounded by pandemic-driven challenges in logistics and staffing.

By March of 2020, we had determined that the global need for vaccines and therapeutics to combat the Covid-19 pandemic, in addition to the already expansive pipeline of non-Covid-related therapeutics, would require us to implement a substantial increase in our manufacturing capacity for the raw materials, assemblies, and technologies used by our customers.

Within the last two years, we initiated an ambitious multi-year expansion strategy aimed at increasing supply security through improving the resilience of our manufacturing operations. Continue reading to learn more about the fundamental principles of this strategy as well as it's execution to not only support the unprecedented mobilization of resources against the virus, but also ensure that the robustness and resilience is in place to protect against future crises.

VIEW THE WHITE PAPER!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of ECM Connection? Subscribe today.

Subscribe to ECM Connection X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to ECM Connection